KTC
IBRX icon

Kistler-Tiffany Companies’s ImmunityBio IBRX Stock Holding History

Kistler-Tiffany Companies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-65
Closed – – 773
2022
Q1 		$0 Hold
65
– – ﹤0.01% 763
2021
Q4 		$0 Hold
65
– – ﹤0.01% 739
2021
Q3 		$1K Hold
65
– – ﹤0.01% 700
2021
Q2 		$1K Hold
65
– – ﹤0.01% 688
2021
Q1 		$2K Hold
65
– – ﹤0.01% 609
2020
Q4 		$1K Hold
65
– – ﹤0.01% 619
2020
Q3 		$0 Buy
+65
New +$648 ﹤0.01% 639

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Kistler-Tiffany Companies's IBRX Position: Q2 2022 in Review

Kistler-Tiffany Companies sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 65 shares.

Kistler-Tiffany Companies first reported a position in IBRX in Q3 2020 and held it in 7 quarters. The position peaked at $2K in Q1 2021. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

  • Kistler-Tiffany Companies reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 65 ImmunityBio shares in Q2 2022.
  • Kistler-Tiffany Companies first reported a position in ImmunityBio in Q3 2020 and held it in 7 quarters.
  • Kistler-Tiffany Companies's ImmunityBio position peaked at $2K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2022, filed 8 Aug 2022.